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Comparison of Disease Progression and Mortality
of Connective Tissue Disease-Related Interstitial
Lung Disease and Idiopathic
Interstitial Pneumonia
S. V. KOCHERIL, B. E. APPLETON, E. C. SOMERS, E. A. KAZEROONI, K. R. FLAHERTY,
F. J. MARTINEZ, B. H. GROSS, AND L. J. CROFFORD
Objective. To compare disease progression and mortality between idiopathic interstitial pneumonia (IIP) and interstitial
lung disease (ILD) due to connective tissue diseases (CTD) including scleroderma, rheumatoid arthritis, systemic lupus,
polymyositis, dermatomyositis, Sjögren’s syndrome, and mixed CTD.
Methods. A case-control study of patients with CTD-ILD (n  46) and IIP controls (n  51), seen at the University of
Michigan between July 1,1998 and June 30,1999 and followed until March 30, 2002, was conducted. Survival analysis and
Cox regression were performed to estimate survival, accounting for demographic and clinical parameters, including
pulmonary function tests and high resolution computed tomography (HRCT) diagnosis and scoring.
Results. Median followup time was 4.4 person-years. Five-year survival in the IIP group was 51.9% (95% confidence
interval [95% CI] 30.8–69.4) versus 43.4% (95% CI 21.1–63.9) in the CTD-ILD group. There were no significant differences
among HRCT diagnostic categories between IIP and CTD-ILD. A fibrotic score >2 was associated with decreased survival
among the entire group. Age at diagnosis and most recent forced vital capacity were significant predictors of mortality
when adjusted for IIP versus CTD-ILD diagnosis, sex, and interstitial score.
Conclusion. Contrary to expectation, CTD-ILD compared with IIP appears to be associated with a worse prognosis when
adjusted for age. A higher fibrotic score is suggestive of decreased survival.
KEY WORDS. Interstitial lung disease; Connective tissue disease; Idiopathic interstitial pneumonia.
INTRODUCTION
Interstitial lung disease (ILD) represents a heterogeneous
group of noninfectious acute and chronic diseases that
involve the lung parenchyma. ILDs are associated with
significant morbidity and mortality, particularly when fi-
brosis occurs. They may either occur as an idiopathic
condition termed idiopathic interstitial pneumonia (IIP),
or in association with many systemic connective tissue
diseases (CTD). The clinical presentations of IIP and CTD-
ILD are similar, with the typical patient presenting with
insidious onset of dyspnea, sometimes associated with a
nonproductive cough, and having bibasilar end-inspira-
tory dry rales on auscultatory examination. Although the
clinical course is variable, there may be a progression to
“end-stage lung” in which there is almost complete loss of
alveolar-capillary units. Patients may eventually develop
cor pulmonale; death usually results from respiratory in-
sufficiency and anoxia (1).
The most common pathologically distinct categories of
ILD are usual interstitial pneumonia (UIP) and nonspecific
interstitial pneumonia (NSIP). Histopathologically, UIP is
characterized by fibrosis, fibroblastic foci, inflammation,
and architectural destruction. NSIP is characterized by a
patchy pattern of inflammation and fibrosis (2). An inter-
national consensus statement in 2001 determined that the
term idiopathic pulmonary fibrosis (IPF) should be as-
signed only to those patients with UIP (3,4). However,
older studies do not make this distinction, and IPF in most
cases represents heterogeneous histopathologic categories.
This may cause difficulty in interpreting survival in pre-
vious studies because the presence of histologic UIP is the
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most important determinant of survival (5). Overall, CTD-
ILDs are more often associated with NSIP than UIP in
comparison with patients with IIP, and NSIP is seen more
frequently in systemic sclerosis (SSc), polymyositis (PM),
dermatomyositis (DM), and mixed connective tissue dis-
eases (MCTD), though rheumatoid arthritis (RA) is more
frequently associated with UIP (2).
In the absence of pathologic material, high resolution
computed tomography (HRCT) has assumed a greater role
in the diagnosis and management of IIP and CTD-ILD. The
diagnostic accuracy of HRCT in conjunction with clinical
evaluation by experienced physicians has been shown to
diagnose IPF with a positive predictive value of 80% (6).
The patterns of ILD on HRCT are described as either
ground glass or honeycombing for alveolar and interstitial
findings, respectively. Honeycombing is defined as cystic
spaces, usually peripheral in location and with the pres-
ence of clearly definable walls. A diffuse or focal area of
hazy increased attenuation in the lung parenchyma, not
associated with obscuration of underlying vessels, is de-
fined as ground-glass opacity (7,8).
HRCT can suggest the underlying pathologic category as
summarized by Hwang et al (9), and has been used to
distinguish between UIP and NSIP. On HRCT, UIP is char-
acterized by irregular subpleural areas of honeycombing
and ground-glass opacity, and NSIP is characterized by
patchy, diffuse areas of ground-glass opacity with associ-
ated areas of consolidation and irregular septal lines (9).
However, reaching a consensus on HRCT categories may
be problematic. Flaherty et al reported results in 96 pa-
tients with IIP for whom both HRCT and histopathologic
data were available (10). The agreement on diagnoses of
definite or probable UIP or NSIP between 2 experienced
thoracic radiologists was only 35%, which improved to
64% when definite and probable categories were com-
bined. An HRCT diagnosis of definite (n  16) or probable
(n  11) UIP was associated with a histologic diagnosis of
UIP 100% of the time. However, when the HRCT diagnosis
was either indeterminate (n  25), probable NSIP (n  25),
or definite NSIP (n  19), the histologic diagnosis was UIP
in 67% of patients. Patients with an HRCT diagnosis of
UIP had a worse prognosis than those with a different
HRCT diagnosis, regardless of pathologic diagnosis. An
alternative to categorizing ILD into pathologic groups by
HRCT is to report fibrosis and alveolar scores (11). A
higher fibrosis score is associated with reduced response
to therapy and reduced survival in patients with IIP (11). It
is thought that patients with CTD-ILD have a better prog-
nosis than patients with IIP (12–14); however, this asser-
tion has been challenged using data from the United King-
dom General Practice Research Database in a cohort
dominated by patients with RA (15).
We hypothesized that patients with CTD-ILD would
have a better prognosis in comparison with patients with
IIP due to earlier diagnosis in the former as a consequence
of nonpulmonary manifestations, and due to more aggres-
sive treatment by rheumatologists accustomed to intensive
immunomodulatory therapies for other manifestations of
CTD. No study to date has compared a large number of
patients in the 2 groups using in-depth analysis of the
impact of HRCT diagnosis and scoring, different treatment
modalities, and the overall disease burden. We compared
mortality among a cohort of patients with IIP and CTD-ILD
including RA, SSc, PM, DM, systemic lupus erythemato-
sus (SLE), MCTD, and Sjögren’s syndrome at a single ter-
tiary care institution. Furthermore, we evaluated these
patients to determine factors associated with mortality and
disease evolution.
SUBJECTS AND METHODS
Subjects. A case-control study design was used. Con-
trols were defined as individuals with IIP (n  51) and
cases were defined as patients with CTD-ILD (n  46).
Subjects were identified based on International Classifica-
tion of Diseases, Ninth Revision, Clinical Modification
codes for IPF or ILD in conjunction with a CTD diagnosis.
A stratified random sample was obtained to yield equiva-
lent-size groups of patients with IIP and CTD-ILD. The
study population included individuals with relevant
codes who visited the University of Michigan as outpa-
tients or inpatients between July 1, 1998 and June 30,
1999, and who were followed until March 30, 2002. At that
time, the diagnosis of IPF was not specific to a histopatho-
logic diagnosis of UIP, as is now the case (3,4). Patients
with CTD were diagnosed and followed in the rheumatol-
ogy clinics at the University of Michigan by the treating
rheumatologist. The clinical diagnoses were validated by
chart review to confirm that patients met the criteria for IIP
and CTD-ILD. The clinical records of each patient were
reviewed for demographic data, clinical history, physical
examination, radiographic data, and pathologic data. This
study was approved by the University of Michigan Insti-
tutional Review Board.
Clinical data. Information directly obtained from pa-
tient charts included date of birth, sex, race, date of death
and/or date lost to followup, onset of ILD, serologic tests
(antinuclear antibody titer and pattern, rheumatoid factor,
anti-Ro, anti-La, anti-Smith, antineutrophil cytoplasmic
antibody titer, anti–Scl-70, anti–Jo-1, and double-stranded
DNA antibodies), smoking activity (active, previous,
never), pulmonary function tests (diffusing capacity for
carbon monoxide [DLCO], forced vital capacity [FVC],
forced expiratory volume [FEV1], and total lung capacity
[TLC]), medications and reasons for discontinuation of
medicine, and echocardiography for right atrial pressure
and right ventricular systolic pressure (RVSP) for cor pul-
monale. Other information abstracted from patient records
included symptom-years (defined as duration of symp-
toms from date of symptom onset to diagnosis) and pack
per year smoking history. A Charlson comorbidity index
(CCI) score was generated for each patient (16). CCI scores
provide additive ordinal values to classify the presence
and degree of comorbid medical illnesses. The prognostic
value of the CCI has also been studied and performed well
in predicting mortality and functional decline (17).
HRCT scoring. HRCTs were reviewed independently by
the 2 thoracic radiologists, without knowledge of clinical
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diagnosis. HRCTs were available for 70 patients. HRCT
examinations were performed using 1.0-mm or 1.5-mm
thick collimation at 1-cm intervals throughout both entire
lungs during inspiration in the supine position on either a
CT HiLite Advantage scanner, HiSpeed Advantage scan-
ner, CTi, LightSpeed, or LightSpeed Ultra (General Electric
Medical Systems, Milwaukee, WI) in nonhelical mode at
the University of Michigan. Previously validated HRCT
scores were used (11). Each lobe was scored on a scale of
0–5 for both alveolar and interstitial abnormality, depend-
ing on the percentage of each lobe involved and the type of
involvement. Ground-glass opacity and honeycombing
represented the alveolar and interstitial findings, respec-
tively. The scores for each lobe were averaged for both
readers for the data analysis. Each radiologist provided a
diagnosis based on HRCT characteristics. If conflicts re-
garding the HRCT diagnosis occurred, the HRCTs were
re-read by both radiologists and a consensus diagnosis was
reached if possible.
Pulmonary function tests. Pulmonary function tests in-
cluding spirometry, lung volumes, and DLCO of the lungs
were performed at the University of Michigan. Data col-
lected from pulmonary function tests included FEV1, FVC,
TLC, and DLCO. Results of the pulmonary function tests
were expressed as percentage of predicted (ppd) values for
the patient’s age, sex, and height. Mean values for each of
these pulmonary function test parameters at baseline were
compared with the mean of all available values for each
patient to evaluate their predictive value.
Statistical analysis. Demographic characteristics were
compared between the IIP and CTD groups by 2-sample
t-tests or chi-square tests, as appropriate for continuous
and categorical variables, respectively. Unless otherwise
specified, continuous measures are expressed as mean 
SD. One-way analysis of variance was used to compare
continuous measures between the CTD-ILD groups. Sur-
vival analysis was performed using left-truncated Kaplan-
Meier estimates. The left-truncated approach adjusts for
survival bias (individuals with longer survival are more
likely to be included than those with short survival in
prevalence studies). Therefore, we estimated the probabil-
ity of survival as a function of time since diagnosis, with
the risk of death restricted to the observation period, i.e.,
after July 1, 1998. Similarly, left-truncated univariate and
multivariable Cox proportional hazards regression were
used to estimate hazard ratios. Testing of the proportional
hazards assumption was performed. Survival curves were
compared using log-rank tests. Additional Kaplan-Meier
estimates comparing the survival functions between pa-
tients with IIP and those with CTD-ILD were adjusted for
age at diagnosis (standardized to age 40), by calculation of
separate Cox regression estimates of the baseline survivor
functions for each group.
Pulmonary function tests were modeled in several dif-
ferent ways, due to their time-varying nature and lack of
uniformity in the timing of pulmonary function test eval-
uations in the study population. FVC and FEV1 were eval-
uated more frequently than TLC and DLCO, therefore pul-
monary function test analyses focused on FVC and FEV1.
An intrapatient mean was computed for each type of pul-
monary function test (FVCppd, FEV1ppd, TLCppd, and
DLCOppd). Also, the most recent FVCppd and FEV1ppd
values per patient prior to the end of followup were deter-
mined. Data management and analysis were performed
using Stata version 8.0 (Stata, College Station, TX).
RESULTS
Demographics. Baseline patient characteristics are
summarized in Table 1. A higher proportion of patients
with CTD-ILD had never smoked compared with those
with IIP (52% versus 31%; P  0.062). Although both
groups were predominantly white, the overall racial dis-
Table 1. Demographic features of patients with idiopathic interstitial pneumonia (IIP) and connective tissue disease-associated










W AA Unknown Asian/Hispanic Active Never
IIP 51 63  12 51 78 2 16 4 1.6  0.8 14 31
CTD-ILD 46 51  13† 65 70 24† 4 2 1.8  1.3 17 52
RA 14 58  10 50 86 7 0 7 1.78  1.25 29 29
SSc 11 48  15 73 45 45 9 0 1.8  1.25 9 55
MCTD 6 52  17 83 83 17 0 0 2.8  2.31 17 67
UCTD 1 41  NA 100 100 0 0 0 1  NA ‡ ‡
PM 4 49  10 100 75 0 25 0 1.25  0.5 0 75
DM 5 41  10 40 40 60 0 0 1  0 20 60
SLE 2 47  21 100 50 50 0 0 2  1.41 0 100
SS 2 54  10 50 100 0 0 0 2.5  2.1 0 100
Other 1 41  NA 0 100 0 0 0 2  NA 100 0
* Unless otherwise indicated, values are percentages. CCI  Charlson Comorbidity Index; F  female; W  white; AA  African American; RA 
rheumatoid arthritis; SSc  systemic sclerosis; MCTD  mixed connective tissue disease; UCTD  undifferentiated connective tissue disease; NA 
not applicable; PM  polymyositis; DM  dermatomyositis; SLE  systemic lupus erythematosus; SS  Sjögren’s syndrome.
† P  0.05
‡ Data is missing/unknown if the sum of active and never is 100%.
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tribution differed significantly (P  0.002); 24% of the
CTD-ILD group was African American versus 2% in the IIP
group. Patients with CTD-ILD were significantly younger
than those with IIP (mean  SD 51  13 years versus 63 
12 years; P  0.001). The mean  SD number of symptom-
years was similar (2.1  2.8 years versus 1.6  1.7 years;
P  0.34); however, these data were only available for 31
patients with IIP and 36 patients with CTD-ILD. Sex dis-
tribution and mean CCI scores were also similar between
groups.
High resolution CT. HRCTs were available and scored
on 70 patients (36 IIP and 34 CTD-ILD). A consensus HRCT
diagnosis was established for 58 patients (83%). Among
the 31 patients with IIP, 45% had UIP and 32% had NSIP;
and among the 27 patients with CTD-ILD, 41% had UIP
and 37% had NSIP (Table 2). Some patients with a clinical
diagnosis of ILD also had other HRCT diagnoses, including
emphysema in both groups and rheumatoid nodules in the
CTD-ILD group. There were no statistically significant dif-
ferences in the diagnostic categories between IIP and CTD-
ILD (P  0.356). In the CTD-ILD group, there was also no
significant difference in the HRCT diagnosis by CTD group
(P  0.114); however, the patients with SSc were more
frequently classified as NSIP (63%) and patients with RA
were more frequently classified as UIP (56%).
HRCT fibrotic and alveolar scores were not significantly
different between the 2 groups (P  0.619) (Table 2).
Among the patients with CTD-ILD, fibrotic scores differed
significantly, with average scores being higher among pa-
tients with SSc and RA (P  0.016). Alveolar scores did
not vary significantly between patients with CTD-ILD (P 
0.826). A fibrotic score 2 was strongly associated with an
HRCT diagnosis of UIP; 76% of patients with UIP had a
fibrotic score 2, versus 5% of patients with NSIP (P 
0.000).
Tests of pulmonary function. Pulmonary function test
data were available for 96 patients; FVC and FEV1 were
available for 96 patients, TLC for 55 patients, and DLCO for
62 patients. There was no statistical difference in mean
functional measures between the IIP and CTD-ILD groups
(Table 3). FVCppd or FEV1ppd were not correlated with
interstitial score. Mean FVCppd was negatively correlated
with alveolar score (r  0.316, P  0.008), but FEV1ppd
was not.
Mortality. One patient was excluded from the survival
estimates because the date of diagnosis was unavailable.
The total followup time was 204.8 person-years, with a
median of 4.4 person-years (interquartile range 2.0–8.9
person-years). The 5-year survival for both groups was
48.9% (95% confidence interval [95% CI] 33.5–62.6).
Five-year survival in the IIP group was 51.9% (95% CI
30.8–69.4) compared with 43.4% (95% CI 21.1–63.9) in
the entire CTD-ILD group. The overall survival between
groups appears to be similar, though formal significance
testing is not applicable because the survival curves cross
at approximately 7.2 years after diagnosis (Figure 1A).
Because the CTD-ILD group was significantly younger,
Kaplan-Meier estimates were also adjusted for age at diag-
nosis (Figure 1B); although survival appears to improve in
the IIP group relative to the CTD-ILD group when adjusted
for age, the apparent difference is not significant (P 
0.267). There was also no correlation of RVSP or his-
topathologic diagnosis with mortality, although this ana-
lysis was limited due to the few number of patients with
this data available.
HRCT fibrotic score was a useful discriminator (Figure
2). An interstitial (fibrotic) score 2 predicted mortality
among the entire group (P  0.059 by log rank test). A
similar trend was seen among the CTD-ILD group, though
significance was not tested because the curves crossed at
2.3 years. There was a trend towards decreased survival
corresponding to an HRCT diagnosis of UIP compared
with NSIP in both groups; however, because this analysis
was restricted to the 45 patients with either UIP or NSIP,
there was insufficient power to reach statistical signifi-
cance (P  0.228). Also, recalling that a fibrotic score 2
was strongly associated with an HRCT diagnosis of UIP,
Table 2. High resolution computed tomography (HRCT) diagnoses and scores for idiopathic interstitial pneumonia (IIP) and
connective tissue disease-associated interstitial lung disease (CTD-ILD) groups*
HRCT diagnoses
HRCT scores





IIP 31 6 32 45 10 6 36 1.5  0.9 1.3  1.1
CTD-ILD 27 0 37 41 4 19‡ 34 1.4  1.0 1.2  0.9
RA 9 0 11 56 11 22 11 1.6  1.0 1.2  1.1
SSc 8 0 63 38 0 0 9 1.7  1.0 1.3  1.0
SLE 1 0 0 100 0 0 1 3.8  NA 0  NA
PM 3 0 67 33 0 0 3 0.7  0.2 1.5  1.1
DM 2 0 100 0 0 0 5 0.8  0.4 1.4  0.6
MCTD 4 0 0 25 0 75 5 0.8  0.7 1.3  1.0
* Unless otherwise indicated, values are percentages. HRCT was not available for patients with Sjögren’s Syndrome or undifferentiated connective
tissue disease. NSIP  non-specific interstitial pneumonitis; UIP  usual interstitial pneumonitis; HP  hypersensitivity pneumonitis. See Table 1 for
additional definitions.
† Includes emphysema.
‡ Includes emphysema, rheumatoid nodules.
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the relationship between fibrotic score and survival may
be confounded by HRCT diagnosis. It is not feasible to
examine their independent effects in a multivariable Cox
model due to the small size of the subset where an HRCT
consensus diagnosis of NSIP or UIP could be reached.
The univariate and multivariable Cox models showed
that the age at diagnosis was found to be a significant
predictor of mortality; the hazard of death increased by 4%
for every 1-year increase in age (P  0.027). The most
recent values of FVCppd and FEV1ppd were shown to be
inversely related with hazard of death; both demonstrated
a 2% decrease in hazard for every unit increase of FVCppd
or FEV1ppd. Age at diagnosis and most recent FVC re-
mained significant in the multivariable model including
IIP and CTD-ILD diagnosis, sex, and interstitial score 2.
Because of the high degree of collinearity between FVC
and FEV1, these variables were not included in the same
model. However, results were similar when FEV1 was
substituted for FVC. There was no evidence for interac-
tions between variables included in the multivariable
model.
Treatment effect. The various treatment modalities re-
ceived by each of the groups were compared (Table 4).
There was a significantly greater use of cyclophospha-
mide, methotrexate, and intravenous corticosteroids in the
CTD-ILD group. Prednisone use and dose was not signifi-
cantly different between the 2 groups. Survival was not
associated with treatment with cyclophosphamide, meth-
otrexate, or corticosteroids. Azathioprine use was signifi-
cantly higher in the IIP group versus the CTD-ILD group
(67% versus 41%; P  0.029), though mean daily dose
among those taking azathioprine was similar (124  34
mg/day versus 118  43 mg/day). Furthermore, azathio-
prine use was associated with nonsignificant improvement
in survival among the total group (P  0.078); when strat-
ified by IIP versus CTD-ILD, the improved survival per-
sisted among the CTD-ILD group (P  0.084), but not the
IIP group (P  0.636). However, because of confounding by
indication (i.e., disease features such as severity impacting
choice of pharmacologic intervention), caution must be
applied when interpreting the associations between treat-
ment and survival.
DISCUSSION
ILD remains difficult to treat and is a significant cause of
mortality in patients with CTD. This study confirms the
poor prognosis in ILD and reveals that a CTD diagnosis
does not confer a survival benefit compared with idio-
pathic disease. Our data suggest that the survival rate in
the CTD-ILD group is in fact worse, when adjusting for age.
Our study also demonstrates that an HRCT fibrosis score
2 is associated with increased mortality in patients with
IIP and CTD-ILD.
HRCT is now commonly used to diagnose and follow
ILD. As in the present study, an HRCT diagnosis of UIP
and a fibrosis score 2 in patients with IIP were previously
demonstrated to be associated with increased mortality
(10,11). The usefulness of a fibrosis score rather than reli-
ance on an HRCT diagnosis is demonstrated by the fact
that a consensus diagnosis between 2 experienced radiol-
ogists could only be reached for 83% of patients. Our
study relied on HRCT due to the absence of confirmatory
pathologic diagnoses in most patients. However, even with
lung biopsies available, there can be interlobar and intralo-
bar histologic variability, and patients with an HRCT di-
agnosis of NSIP often have a histopathologic diagnosis of
UIP (5). It has also been shown that patients with a typical
HRCT appearance of UIP experience the highest rate of
mortality when compared with patients with NSIP and
those with histopathologically proven UIP that do not
have the typical HRCT characteristics of UIP (10). A his-
topathologic diagnosis of UIP nevertheless has important
implications, as the 5-year survival in IIP was 20–40% in
patients with UIP compared with 70–85% in patients with
NSIP (18).
Other studies examining the HRCT or histopathologic
patterns of patients with CTD as predictors of survival
were different from the present study in design, likely
accounting for differing conclusions. A previous study of
Table 3. Predicted percentage for pulmonary function tests for idiopathic interstitial pneumonia (IIP) and connective tissue
disease-associated interstitial lung disease (CTD-ILD) groups*
Pulmonary function test
No. FVC FEV1 TLC DLCO
IIP 50 65  19 73  19 77  18 43  17
CTD-ILD 46 64  18 69  19 77  18 47  19
RA 14 67  11 74  11 79  15 40  16
SSc 11 64  17 69  18 74  15 41  17
SLE 2 48  4 53  6 62  0 22  16
PM 4 51  17 54  17 72  5 60  13
DM 5 59  24 62  25 70  19 57  24
SS 2 53  17 54  20 71  11 56  0
MCTD 6 69  19 75  18 85  24 58  16
UCTD 1 120  NA 122  NA 132  NA 81  NA
Other 1 49.9  NA 51.4  NA 58  NA 43.4  NA
* Values are mean  SD. FVC  forced vital capacity; FEV1  forced expiratory volume; TLC  total lung capacity; DLCO  diffusing capacity for
carbon monoxide. See Table 1 for additional definitions.
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patients with SSc showed that NSIP was the most frequent
histopathologic pattern; however, there was no survival
difference between NSIP and UIP, and outcome was linked
more strongly to DLCO trends than to histopathologic di-
agnosis (19). A recent study of patients with PM/DM also
demonstrated a higher prevalence of NSIP (80%) and an
absence of honeycombing on HRCT (14). These patients
had a much better survival rate than historical controls
with IIP. In another study of PM/DM, patients with his-
topathologic UIP had reduced survival (20). In our CTD-
ILD sample, 20% of the patients had PM/DM. We did not
find a survival difference between individual diagnostic
groups and the group as a whole, but we likely did not
have sufficient numbers of patients with each CTD diag-
nosis to find small survival differences. In agreement with
the present study, another recent study challenged the
assertion that patients with CTD-ILD have a better out-
come than those with idiopathic disease (15). Based on
data from the United Kingdom General Practice Research
Database, Hubbard and Venn found that the median sur-
vival time was 2.4 years for patients with CTD-ILD versus
2.6 years for patients with IIP (15). The predominant CTD
Figure 1. A, Kaplan-Meier estimates comparing survival between patients with idiopathic
interstitial pneumonia (IIP) (n  50) and connective tissue disease-related interstitial lung
disease (CTD-ILD) (n  46) groups. Each tick mark corresponds to a time of patient
censoring. B, Comparison of survival rates between IIP and CTD-ILD groups when adjusted
for age at diagnosis (P  0.267 based on bivariate Cox regression model).
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in this study was RA (80%) rather than SSc, PM, or DM,
and the extent to which the category of ILD impacted
overall outcome was unclear.
Our study also demonstrated clinical utility for pulmo-
nary function testing. The most recent values of FVCppd
and FEV1ppd demonstrated a 2% decrease in hazard for
every unit increase of FVCppd or FEV1ppd. The univariate
and multivariable Cox models demonstrated that the age at
diagnosis and most recent FVC were significant predictors
of mortality. The hazard of death increased by 4% for
every 1-year increase in age, and 4% for every unit de-
crease of FVCppd, when adjusted for diagnosis of IIP ver-
sus CTD-ILD, sex, and interstitial score. It has previously
been shown that among patients with SSc, former smokers
are at a very high risk for rapid deterioration of pulmonary
function and have significantly greater rates of loss of FVC
and DLCO than either nonsmokers or current smokers (21).
In our study, we observed a greater number of patients in
the CTD-ILD group who had never smoked, though there
was no difference in mean values for pulmonary function
tests. We were unable to correlate HRCT scores with pul-
monary function test in this study, likely due to the retro-
spective design. A prospective study with paired HRCT
and pulmonary function test evaluations may demonstrate
a closer relationship between these measures.
As this and other studies have shown, fibrosis is predic-
tive of poor clinical outcome. Histologically, fibroblastic
foci are seen in UIP, and Flaherty et al showed that pa-
tients with UIP associated with CTD have fewer fibroblas-
tic foci and improved survival compared with those with
idiopathic UIP (22). In that study, however, there were
only 9 patients with CTD in comparison with 99 patients
with idiopathic UIP, which could account for the different
results compared with the present study. The improved
survival in patients with CTD could also be confounded by
lead time bias accounting for the difference.
There were no significant survival differences between
the groups based on treatment modalities, including cyto-
Figure 2. Kaplan-Meier estimates comparing survival by high resolution computed tomog-
raphy fibrotic score among 70 patients with idiopathic interstitial pneumonia and connec-
tive tissue disease-related interstitial lung disease (P  0.059). Each tick mark corresponds
to a time of patient censoring.
Table 4. Treatment modalities for idiopathic interstitial pneumonia (IIP) and connective
tissue disease-associated interstitial lung disease (CTD-ILD) groups*
IIP (n  51) CTD-ILD (n  46) P
Oral prednisone 34 (66.7) 38 (82.6) NS
IV corticosteroids 2 (3.9) 11 (23.9) 0.015
Cyclophosphamide 2 (3.9) 15 (32.6) 0.000
Cyclophosphamide oral dosage† 125  35 mg/day 96.9  28 mg/day NS
Methotrexate 0 (0%) 15 (32.6%) 0.000
Azathioprine 34 (66.7%) 19 (41.3%) 0.029
Azathioprine dosage† 124  34 mg/day 118  43 mg/day NS
* Unless otherwise indicated, values are frequency (percentage) or mean  SD. NS  not shown; IV 
intravenous.
† Mean dosage among those taking the medication.
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toxic agents. This could reflect the lack of available agents
for optimal management of ILD, or it could reflect diagno-
sis at a time when intervention with the currently used
immunosuppressive agents is no longer useful. There are
few randomized, controlled studies of patients with IIP
demonstrating efficacy of treatment. Antiinflammatory
agents, including corticosteroids, cytotoxic agents, and an-
tifibrotic agents such as colchicine, have not demonstrated
efficacy in patients with IPF (23). A prospective, double-
blind, randomized, placebo-controlled trial suggested that
azathioprine and corticosteroids may improve lung func-
tion tests and have a potential survival advantage in IIP
(24).
In the CTD-ILD group, early treatment with cytotoxic
agents in the patients with active alveolitis is suggested in
RA, SSc, SLE, and MCTD, and less so in Sjögren’s-related
ILD (25). Corticosteroids used in the early stages improve
pulmonary function tests and alveolitis, and there is prom-
ising evidence for the successful treatment of alveolitis
with cyclophosphamide (25); however, prospective, ran-
domized trials are required for better evaluations of these
treatment modalities (26). Retrospective studies of patients
with SSc-related ILD have shown significant improvement
in pulmonary function tests with either oral or intravenous
cyclophosphamide (27,28), and randomized, double-
blind, placebo-controlled trials with oral cyclophospha-
mide are currently ongoing. Uncontrolled studies of pa-
tients with RA-related ILD have used methotrexate (29),
azathioprine (30), and cyclosporine (31), either alone or in
combination with steroids, and have suggested improve-
ment in pulmonary function tests. Case reports in RA-
related ILD indicated a beneficial effect of infliximab over
1 year and resulted in improvement in dyspnea, cough,
exercise intolerance, and stabilized pulmonary function
tests (32). Prospective, randomized, controlled trials are
required to determine the optimal management of CTD-
ILD. Our data suggest that patients with an HRCT fibrosis
score 2 may have a better prognosis, and patients with
ILD could be stratified based on the fibrotic score. Study
designs should consider this in the randomization scheme
or as a covariate in the analysis.
There are a number of limitations to this study, a major
one being the retrospective nature of the data collection,
which impacted the uniformity of the data available for
evaluation. For example, patients with IIP may have fea-
tures of CTD that could be identified with specific sero-
logic tests that were not routinely collected, making it
possible that some patients were misclassified. The cause
of death was also not determined in either the IIP or in the
CTD-ILD group, and we cannot be certain that the cause of
death was always associated with lung disease. However,
the fact that specific features of the pulmonary process
were predictors of mortality in both groups suggests that
lung disease played an important role in mortality. We
also were not able to systematically assess the hemody-
namic parameters and ascertain if pulmonary hyperten-
sion affected the survival data in the CTD-ILD group due to
the retrospective nature of the study. The onset of symp-
toms in the 2 groups also could not be accurately deter-
mined from the patient’s history. We also acknowledge the
fact that there is a lack of data studying the effects of
targeted biologic therapy, such as the effect of tumor ne-
crosis factor  inhibitors on the mortality differences in the
CTD-ILD group. We hope to conduct prospective studies
in the future to determine if there would be significant
survival differences when these agents are used.
In summary, patients with either IIP or CTD-ILD have a
poor prognosis and similar mortality rate. This appears to
be irrespective of the CTD diagnoses or treatment modal-
ities. However, in each subset of CTD-ILD there are limited
numbers of patients to draw conclusions between each
CTD diagnosis. Our data support the notion that the most
important factor contributing to poor outcome in patients
with CTD is the presence of fibrosis. Therefore, it is im-
perative for rheumatologists to have screening guidelines
for ILD with the goal of diagnosing patients with CTD-ILD
before fibrosis occurs. We suggest that HRCTs obtained
while screening for CTD patients with respiratory symp-
toms should be scored for fibrosis because an HRCT fibro-
sis score 2 predicts a subset of CTD patients with a worse
prognosis, regardless of the HRCT diagnostic category. It
could also be suggested that an HRCT diagnosis of UIP or
high HRCT fibrosis scores could identify these patients
with poor prognosis without confirmatory biopsies. Fur-
ther research and prospective studies to compare the 2
groups with HRCT scoring, pulmonary function tests, clin-
ical parameters, and treatment modalities will better de-
lineate ILD and the prognostic implications in the optimal
patient management of ILD in patients with CTD-ILD.
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